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Prostate cells contain speciﬁc receptors for 1α,25-dihydroxyvitamin D [1α,25(OH)2D] or calcitriol, the active form of vitamin
D. 1α,25(OH)2D is known to inhibit the proliferation and invasiveness of prostate cancer cells. These ﬁndings support the use
of 1α,25(OH)2D for prostate cancer therapy. However, 1α,25(OH)2D can cause hypercalcemia, analogs of 1α,25(OH)2Dt h a ta r e
less calcemic but exhibit potent antiproliferative activity would be attractive as therapeutic agents. To accomplish these goals,
diﬀerent strategies, based on metabolism, molecular mechanism of actions, and structural modeling, have been taken to modify
the structure of vitamin D molecule with the aims to improve the eﬃcacy and decrease the toxicity of vitamin D to treat diﬀerent
diseases.Duringthepastfourdecades,over3,000analogshavebeensynthesized.Inthispaper,wediscussthedevelopmentandthe
biological analysis of a unique class of vitamin D analogs with a substitution at the carbon 2 of 19-nor-1α,25(OH)2D3 molecule
for potential application to the prevention and treatment of prostate cancer as well as other cancers.
1.Introduction
Prostate cancer is the most prevalent nonskin cancer among
older men, with 190,000 new cases in 2010, and the second
leading cause of cancer deaths among US men after lung
cancer with approximately 30,000 deaths projected in 2011
[1]. Androgen deprivation is a common practice for tumors
that are ineligible for or fail to respond to surgery or
radiation therapy. Although the majority of men respond
to androgen deprivation, the median duration of response
is only about 2 years [2]. Great eﬀorts have been made to
develop new therapies to prolong the survival of patients
with prostate cancer that fails to response to androgen
deprivation therapy, such as docetaxel- or carbazitaxel-
based chemotherapy, immunotherapy with sipuleucel-T, or
abiraterone acetate. However, their eﬀectiveness is limited to
only a few months gain in survival [3].
It is now well established that the growth of prostate
cells is regulated not only by androgens but also by vitamin
D. Human prostate cells express vitamin D receptor (VDR)
for 1α,25-dihydroxyvitamin D [1α,25(OH)2D] (Figure 1),
the active form of vitamin D [4]. Numerous reports have
demonstrated that 1α,25(OH)2D stimulates diﬀerentiation
and inhibits the proliferation, invasiveness, and metastasis of
prostate cancer cells [4]. These ﬁndings strongly support the
use of vitamin D-based therapies for prostate cancer treat-
ment once androgen deprivation has failed. However, the
resultsofearlyclinicaltrialsusing1α,25(OH)2D3 (Calcitriol)
indicated that the hormone caused serious hypercalcemic
and hypercalciuric side eﬀects [5, 6]. Therefore, analogs of
1α,25(OH)2Dw i t hl e s sc a l c e m i ca c t i v i t yb u tw i t hp o t e n t
antiproliferative activity would be attractive agents.
2. History of the Synthesis of
VitaminDAnalogs
Vitamin D was discovered a century ago because of an
epidemic of a childhood bone disease, rickets [7]. It was
concludedthattheprimaryfunctionofvitaminDinhumans
was to enhance the intestinal absorption of calcium and
phosphate, two major ingredients of bones, to maintain their
serum concentrations at a suﬃcient level to facilitate bone
calciﬁcation and other cellular functions [8]. It was later
realized that vitamin D itself was not active and required
a series of hydroxylation steps ﬁrst in the liver and then2 ISRN Urology
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Figure 1: Structures of 1α,25(OH)2D3,2 α-3-hydroxypropoxy-1α,25(OH)2D3 (O2C3) and 19-nor-2α-3-hydroxypropyl-1α,25(OH)2D3
(MART-10).
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Figure 2: Julia coupling reaction between the A-ring C5 and the CD-ring C6 positions. TBS: tert-butyldimethylsilyl group as a protecting
group, MOM: methoxymethyl group as a protecting group, LiHMDS: lithium hexamethyldisilazide, THF: tetrahydrofuran, (+)-CSA: (+)-
10-camphorsulfonic acid. The structures are written with steroidal numbering.
in the kidneys to form 25-hydroxyvitamin D [25(OH)D]
and 1α,25(OH)2D, respectively, before it became active [8].
Although vitamin D was widely used in the 1940s to treat
various forms of skin diseases, such as lupus vulgaris [9],
cutaneous tuberculosis [10], and psoriasis [11], it was not
until late 1970s that vitamin D receptors were shown to be
presentinmanycellsandtissueswhichwerenotknowntobe
associated with calcium and phosphorus homeostasis [12].
Subsequently, it was shown that 1α,25(OH)2Dw a sc a p a b l e
of inhibiting the growth of various types of cancer cells [13]
andpromotingthediﬀerentiationofpromyelocyticleukemia
cells (HL-60) to form mature macrophages [14]. The in
vitro cell culture studies were followed by animal studies us-
ing xenograft mouse model and chemically induced cancer
model to demonstrate the eﬀectiveness of 1α,25(OH)2D
in inhibiting the tumor cell growth [4, 15, 16]. However,
1α,25(OH)2Da th i g hd o s e sw h i c hw e r eu s u a l l yr e q u i r e dt o
inhibit tumor cell growth in vivo animal models also raised
serum calcium level and decreased the body weight of the
animals [16]. In human clinical trials, hypercalcemia and
hypercalciuria were also found to be the major side eﬀects of
1α,25(OH)2D when it was administered systemically [5, 6].
To overcome these drawbacks, attempts have been made
to synthesize vitamin D analogs that retain most of the
nonclassical activities of 1α,25(OH)2D but have much lower
calcemic activity in vivo. Several synthetic vitamin D analogs
have been demonstrated to exert promising anticancer
eﬀects with reduced calcemic consequence and even greater
antiproliferative activity than 1α,25(OH)2D[ 16]. Among
those vitamin D analogs, Seocalcitol (EB1089, Leo Phar-
maceutical Products) is one of the most studied synthetic
analogs [17–19]. A considerable number of in vitro and inISRN Urology 3
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Figure 3: Comparison of the eﬀe c to f1 α,25(OH)2D3 and 19-nor-
1α,25(OH)2D3 on the 3H-thymidine incorporation in (a) LNCaP
cells and (b) the primary cultures of prostate cancer cells. Results
are presented as the means ± SD of 5–8 determinations. There is
no diﬀerence between 1α,25(OH)2D3 and 19-nor-1α,25(OH)2D3 at
any dose levels examined. ∗P<0.05, ∗∗P<0.001 versus controls.
vivostudieshavebeencarriedoutwithEB1089andshowthat
the analog is more potent than 1α,25(OH)2Dw i t hr e s p e c t
to the regulation of cancer cell growth and diﬀerentiation,
and the eﬀect of EB1089 on calcium metabolism in vivo
is approximately 50% less than that of 1α,25(OH)2D[ 16].
The anticancer eﬀects of EB1089 were also demonstrated in
vivo in a rat model of mammary gland carcinoma without
inducing hypercalcemia [17, 18]. Similar eﬀects were seen
in an in vivo prostate cancer study where EB1089 inhibited
prostate cancer cell proliferation and reduced tumorigenesis
as well as tumor metastases [19]. Clinical trials with 1α-
hydroxyvitamin D2 (Hectorol) marketed by Genzyme have
been conducted in hormone refractory prostate cancer pa-
tients [20, 21]. In a phase I trial, the authors reported
C
e
l
l
c
o
u
n
t
(
%
o
f
c
o
n
t
r
o
l
)
0
0
20
40
60
80
100
120
10−9 10−8 10−7 10−6 10−12 10−11 10−10 10−9
∗
∗
∗
∗
∗
∗
Concentration (M)
LNCaP cells
MART-10 α,25(OH)2D3 1
Figure 4: The dose-dependent eﬀects of 1α,25(OH)2D3 and
MART-10 on LNCaP cell proliferation. LNCaP cells were
treated with ethanol vehicle or the indicated concentrations of
1α,25(OH)2D3 and MART-10 for one week and then trypsinized
and cell counted with hemocytometer. The results are expressed as
the percent of control of the means ± SD of 3 determinations from
a representative experiment. The experiment was repeated 3 times
with similar results. ∗P<0.05 compared to the previous doses.
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Figure 5: Eﬀect of 1α,25(OH)2D3, and 19-nor-2α-3-hydroxy-
propyl-1α,25(OH)2D3 (MART-10) on the invasion of PC-3 cells.
The results are presented as the means ± SD of 3 determinations.
∗Comparison between control and 1α,25(OH)2D3 or MART-10;
∗∗Comparison between 1α,25(OH)2D3 and MART-10.
that Hectorol was well tolerated with the main toxicities
being hypercalcemia and renal insuﬃciency, and the side
eﬀects were reversible with drug discontinuation [20]. In a
follow-up phase II study, they observed disease stability >6
months in 30% of the patients and the median survival of
21 months, which is higher than the 17.7 months predicted
by the survival nomogram for that patient group [21]. Al-
though the results are less than conclusive, the encouraging
ﬁndings do warrant further studies with vitamin D analogs.4 ISRN Urology
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Figure 6: Binding of MART-10 and 1α,25(OH)2D3 to vitamin D
binding protein (DBP). The binding aﬃnity of 1α,25(OH)2D3 and
MART-10 to vitamin-D-binding protein (DBP) was determined by
the displacement of [3H]-25(OH)D3 from rat serum DBP by indi-
cated concentrations of MART-10 and 1α,25(OH)2D3. The results
are expressed as the percentage of displaced [3H]-25(OH)D3 (B)
over total speciﬁc bound of [3H]-25(OH)D3 (Bo).
Other vitamin D analogs or structural VDR activators, such
as Maxacalcitol (OCT) (Chugai Pharmaceutical Co. Ltd.)
[22], 16-ene analogs (Hoﬀmann LaRoche, Inc.) [23], 19-nor
analogs (Hoﬀmann LaRoche, Inc.) [24], 1α-hydroxyvitamin
D5 [25], and LG190119 (Ligand Pharmaceuticals Inc.) [26],
have been developed and tested in preclinical studies. These
compounds may have promise as therapeutic agents for
cancer and other diseases, with fewer side eﬀects than
1α,25(OH)2D3 and 1α-hydroxyvitamin D2. Other vitamin D
analogswhichhaveshownsomepromisinginvitrobiological
activities include C-20 cyclopropylcalcitriol [27], elocalcitol
[28], Gemini vitamin D analogs [29].
3. Development of the LessCalcemic
19-NorvitaminDAnalogs
19-Norvitamin D compounds in which the ring A methylene
group on C-19 is replaced with two hydrogen atoms
were known to be in existence in 1983 when 19-nor-10-
ketovitamin D derivatives were ﬁrst isolated and identi-
ﬁed from a mixture of vitamin D or 25(OH)D solution
incubated with bovine rumen microbes [30]. Later, 19-
nor-1α,25(OH)2D3 was synthesized by Perlman et al. to
study the structure-activity relationship of 1α,25(OH)2D3
molecule [31]. They reported that this analog induced the
diﬀerentiation of human leukemia HL-60 cells similar to
1α,25(OH)2D3 with little or no calcemic activity [31]. The
ﬁndings led to the synthesis of 19-nor-1α,25(OH)2D2 and
the evaluation of its activity by Slatopolsky et al. [32].
Both19-nor-1α,25(OH)2D2 and19-nor-1α,25(OH)2D3 have
potency similar to 1α,25(OH)2D3 in inducing CYP24A1
promoter activity in a transcription assay and in suppressing
parathyroidhormonesecretioninhemodialysispatientswith
secondary hyperparathyroidism, without inducing hyper-
calcemia or hyperphosphatemia [30–33]. Today, 19-nor-
1α,25(OH)2D2, also called Zemplar or paricalcitol, is an
FDA-approved drug for the treatment of secondary hyper-
parathyroidism. Subsequently, diﬀerent modiﬁcations of the
A-ring, including the synthesis of C-2 modiﬁed 19-norvita-
min D compounds, were accomplished by a signiﬁcant
number of synthetic organic chemists [34–41].
The ﬁrst synthesis of 19-norvitamin D reported by
DeLuca’s group in 1990 is a direct synthesis starting from
25-hydroxyvitamin D3 [31]. Subsequently, a convergent syn-
thetic route was described by the same group, and the
method has become one of the standard ones for the syn-
thesisofnew19-norvitaminDanalogs[42].Thecon-vergent
method consists of a coupling reaction between an A-ring
phosphine oxide with a C1–C7 carbon unit and an 8-keto-
CD-ring with a C17 side chain such as 25-hydroxy Grund-
mann’s ketone.
During the past decade, systematic synthesis of vitamin
D3 analogs with C2-modiﬁcation has been attempted, and a
number of C2-modiﬁed analogs with a greater VDR agonis-
tic activity than 1α,25(OH)2D3 have been successfully syn-
thesized[34,35,42–44].Forexample,asubstitutionwith2α-
methyl, 2α-(3-hydroxypropyl), or 2α-(3-hydroxypropoxy)
groupincreaseditsbindingaﬃnityfortheVDRtwo-tofour-
fold compared to 1α,25(OH)2D3[43–45]. Similarly, several
highly potent VDR antagonists, which belong to a series of
TEI-9647 analogs with C2α functionalization as well as the
24-alkyl modiﬁcation on the lactone ring, have been syn-
thesized [46]. The mechanism of the enhanced C2α-eﬀects
on VDR binding aﬃnity has been revealed by an X-ray co-
crystallographic analysis of the VDR-ligand complexes [47].
The study shows that the terminal hydroxy group of 2α-(3-
hydroxypropyl) or 2α-(3-hydroxypropoxy) substituent plays
an important role in expelling the water molecules in the
ligand binding domain of the VDR to form hydrogen bonds
with arginine-274 residue of the VDR molecule to stabilize
the VDR-ligand complex [47]. Knowing the advantage of
modifying 1α,25(OH)2D3 molecule with “2-substitution” to
enhance VDR binding aﬃnity and “19-demethylenation” to
eliminate calcemic potential, we, therefore, set forth to syn-
thesize C2-substituted 19-nor-1α,25(OH)2D3 analogs using
the convergent synthetic approach developed by DeLuca’s
laboratory[42].However,during thesynthesisof19-nor-2α-
3-hydroxypropyl-1α,25(OH)2D3 (MART-10) and 19-nor-
2β-3-hydroxypropyl-1α,25(OH)2D3 (MART-11), we quickly
realized that the typical coupling reaction between the 2-
substituted 19-nor-A-ring part and the 8-keto-CD-ring part,
that is, C7-C8 connection based on the Horner-Wadsworth-
Emmons reaction, was problematic because of the large 1,2-
steric repulsion between 1α-siloxy and the phenyl groups on
phosphorus atom present in the oxaphosphetane transition
state [34]. We decided to connect one of the double bonds of
the target diene of MART-10/MART-11 between the C5 (A-
ring) and C6 (two carbons elongated CD-ring from the 8-
keto group) positions using the Julia coupling approach, and
the reactions turned out to be successful (Figure 2). Finally,ISRN Urology 5
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the target products were separated using a reversed phase
HPLCtoobtaintwodiastereomers,MART-10(2α-form)and
MART-11 (2β-form) [48].
TheMART-10andMART-11obtainedwerethenstudied
for their VDR binding property using a calf thymus vitamin
D receptor preparation and HL-60 diﬀerentiation potency.
We found that MART-10 and MART-11 had a binding
aﬃnity equal to 100% and 3% of the parent hormone
1α,25(OH)2D3, respectively. However, we observed a 36-
fold and 7-fold greater activity in the induction of HL-60
cell diﬀerentiation by MART-10 and MART-11, respectively,
than by 1α,25(OH)2D3 [35, 49]. The discrepancy between
VDR binding and diﬀerentiation activity can be explained
at least in part by a greater ability in recruiting coactivators,
such as hTIF-2 and hSRC-1, by MART-10 and MART-11
than by 1α,25(OH)2D3 as determined by a high-throughput
screening method developed in our laboratory to study the
interaction between human VDR and cofactors [50].
4. The AntiproliferativeActivityof
19-NorvitaminDAnalogsinProstateCells
Theantiproliferativeactivityof19-norvitaminDanalogswas
ﬁrst studied in LNCaP prostate cancer cells and in primary
cultures of prostate cancer cells using 19-nor-1α,25(OH)2D2
and 19-nor-1α,25(OH)2D3 [50, 51]. It was reported that
19-nor-1α,25(OH)2D2 had antiproliferative activity compa-
rable to 1α,25(OH)2D3, as determined by 3H-thymidine
incorporation [51]. Similarly, 19-nor-1α,25(OH)2D3 was
found to be equipotent to 1α,25(OH)2D3 in the primary
cultures of prostate cancer cells and LNCaP prostate cancer
cells (Figure 3)[ 52]. After we obtained a series of 19-
nor-1α,25(OH)2D3 analogs modiﬁed at C-2 position with
diﬀerent hydrocarbon moieties, we began to study their
antiproliferative activity in PZ-HPV-7 prostate cells, a cell
line derived from the epithelial zone of a normal prostate
and obtained from ATCC. Among them, 19-nor-2α-3-hyd-
roxypropyl-1α,25(OH)2D3 (MART-10) and 19-nor-2β-3-
hydroxypropyl-1α,25(OH)2D3 (MART-11) were found to be
about 500- to 1,000-fold more active than 1α,25(OH)2D3
[53].
Comparison of the inhibitory eﬀect of MART-10 with
1α,25(OH)2D3 on the cellular proliferation was then carried
out in androgen-dependent LNCaP and androgen-indepen-
dentPC-3prostatecancercellsbyhemocytometercellcount-
ing. Similar to the ﬁndings using PZ-HPV-7 cells, MART-
10 is about 1,000-fold more active than 1α,25(OH)2D3 in
inhibiting LNCaP (Figure 4)[ 54] and PC-3 prostate cancer
cell proliferation (D. Iglesias-Gato et al., unpublished data).
5. Metabolism of MART-10 by 24-Hydroxylase
(24-OHaseor CYP24A1)
CYP24A1 is one of the three major enzymes involved in
the metabolism of vitamin D endocrine system. The gene6 ISRN Urology
encoding this enzyme is highly inducible by 1α,25(OH)2D3
or its analogs, and, therefore, the induction of this gene
has been used as an index for the biological potency of
new analogs [55, 56]. Most importantly, CYP24A1 serves as
a principle mechanism to terminate the biological actions
of 1α,25(OH)2D3 or its analogs through 24-hydroxylation-
dependent catabolic pathway [57]. Because of this important
role,speciﬁcinhibitorsofCYP24A1havebeendevelopedand
used to enhance and prolong the actions of the natural hor-
mone [57]. Alternatively, analogs which are more resistant to
the catabolic degradation of CYP24A1 will have longer half-
life and potentially more bioavailablity than 1α,25(OH)2D3.
In a series of experiments comparing the expression of
CYP24A1 in response to 1α,25(OH)2D3 and MART-10 treat-
ment in LNCaP and PC-3 prostate cancer cells, we observed
that MART-10 was capable of inducing CYP24A1 expression
atalowerconcentrationandtoagreaterextent[54]andwith
a longer duration than 1α,25(OH)2D3 (D. Iglesias-Gato et
al., unpublished observation). The longer duration suggests
that MART-10 is more resistant to CYP24A1 degradation. To
ﬁnd out whether this was the case, we then used a cell-free
CYP24A1 reconstituted system [54] to determine the kcat/Km
value, an indicator of enzyme susceptibility, of MART-10 or
2α-(3-hydroxypropoxy)-1α,25(OH)2D3 (O2C3) (Figure 1)
used as a substrate. We found that MART-10 had a kcat/Km
of 0.33 which is about 1/10 of what was found with O2C3
(kcat/Km = 3.0). Since the kcat/Km for O2C3 is about 1/50
of 1α,25(OH)2D3 [58], the kcat/Km for MART-10 is about
1/500 of 1α,25(OH)2D3.T h ekcat/Km data suggest that the
additionof3-hydroxypropylgroupatcarbon2intheMART-
10 molecule may hinder the contact of the side-chain of
MART-10 molecule to the heme group of CYP24A1 and
results in a very poor 24-hydroxylation and, in turn, much
less degradation of MART-10 by CYP24A1. The conclusion
is supported by a docking model of MART-10 sit inside the
substrate-binding pocket of the human CYP24A1 (Personal
communication with Drs. Yamamoto and Sakaki).
6.MART-10 Is aMore PotentInhibitorof
CancerCellInvasion
In addition to its higher activity in inhibiting prostate
cancer cell proliferation, MART-10 is about 10-fold more
active than 1α,25(OH)2D3 in inhibiting PC-3 cell invasion
(Figure 5)[ 53]. Similar results were obtained with 19-nor-
2β-3-hydroxypropyl-1α,25(OH)2D3 (unpublished observa-
tion). MART-10 also exhibited a greater downregulation of
matrix metalloproteinase-9 (MMP-9) expression at both the
transcriptional and translational levels (D. Iglesias-Gato et
al., unpublished observation). Since MMP-9 is an enzyme
involved in the cell invasion pathway [59, 60], the greater
downregulation of MMP-9 activity may be responsible
for the more potent anti-invasion eﬀect observed in the
presence of MART-10. In turn, the greater eﬀect on MMP-
9 gene expression and the expression of CYP24A1 and
g e n e si n v o l v e di nc e l lp r o l i f e r a t i o nm a yb ed u et oi t sm o r e
profound VDR transactivation activity in prostate cancer
cells [54, 61].
Table 1: Comparison of biological activity between 1α,25(OH)2D3
and MART-10 in prostate cancer cells.
Anti-
proliferation
Anti-
invasion
CYP24A1,
Kcat/Km
DBP
Binding
1α,25(OH)2D3 11 1 1
MART-10 1,000 100 1/500 1/25
7.MART-10 Binds to Vitamin-D-Binding
Protein(DBP) witha Lower Afﬁnity
Than 1α,25(OH)2D3
The bioavailability of MART-10 in circulation was examined
by measuring its binding aﬃnity to serum DBP (Kd, deﬁned
as the concentration of 1α,25(OH)2D3 or MART-10 at
which a 50% reduction in [3H]-25(OH)D3 binding to DBP
was observed). The Kds for MART-10 and 1α,25(OH)2D3
are 17.5μM and 0.67μM, respectively, indicating that the
binding aﬃnity of MART-10 for DBP is about 25-fold less
than that for 1α,25(OH)2D3 (Figure 6)[ 54]. The lower DBP
binding aﬃnity for MART-10 will allow more MART-10 to
be translocated into the target cells, including the prostate.
8. Conclusion
Vitamin D has been discovered as an antirachitic agent for
almost a century. For more than half a century since its
discovery, vitamin D was believed to be involved only in
calcium and phosphate homeostasis. The realization that
vitamin D (vitamin D2 and vitamin D3) itself was not active
and required two successive hydroxylation steps to produce
i t sa c t i v ef o r m ,1 α,25(OH)2D3, led to the ﬁnding in 1979
that VDR was present in many tissues not related to cal-
cium and phosphate metabolism. Subsequently, many non-
classical actions of 1α,25(OH)2D3 were revealed, includ-
ing antiproliferation, anti-invasion, proapoptosis, prodif-
ferentiation, immune regulation, and so forth, (Figure 7).
Although 1α,25(OH)2D3 exhibited potent antitumor eﬀects
onprostatecancermodels,hypercalcemiaandhypercalciuria
side eﬀects were quickly realized in animal models and
human clinical trials. The lethal side eﬀects, thus, limit
the application of 1α,25(OH)2D3 clinically. Consequently,
several thousand vitamin D analogs were synthesized with
an intention to eliminate or lessen the side eﬀects and
at the same time to enhance their antitumor activity. So
far, none of the analogs have shown clinically satisfactory
results. In this paper we describe the synthesis of a novel
analog of 1α,25(OH)2D3, called MART-10 and present in
vitro data using normal, androgen-dependent LNCaP, and
androgen-independentPC-3cellculturemodels.Comparing
to 1α,25(OH)2D3, MART-10 is 10 times more active in
stimulating VDR transactivation in LNCaP cells, about 500-
to 1000-fold more active in inhibiting the proliferation of
these three types of prostate cells, 10 times more potent in
inhibiting PC-3 invasion, at least 500-fold more resistant
to CYP24A1-dependent degradation and has about 25-fold
lower binding aﬃnity to DBP (Table 1). In addition, MART-
10 did not raise serum calcium when it was injected intoISRN Urology 7
rats [D. Iglesias-Gato et al., unpublished observation]. The
unique properties of MART-10 suggest that this analog has
a potential as a new regimen for prostate cancer treatments
through all stages of the disease.
Abbreviations
1α,25(OH)2D3:1 α,25-dihydroxyvitamin D3
VDR: Vitamin D receptor
DBP: Vitamin D binding protein
MMP-9: Matrix metalloproteinase-9
O2C3: 2α-(3-hydroxypropoxy)-1α,25(OH)2D3
MART-10: 19-nor-2α-(3-hydroxypropyl)-
1α,25(OH)2D3
MART-11: 19-nor-2β-(3-hydroxypropyl)-
1α,25(OH)2D3.
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